Entropy Neurodynamics Passes All Nine Resolutions at 12 November 2026 AGM

Manish Choudhary

12 November 2026 04:54 PM AEDT

Entropy Neurodynamics Passes All Nine Resolutions at 12 November 2026 AGM

Image Source: Krish Capital Pty Ltd

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Entropy Neurodynamics Limited (ASX:ENP), a clinical-stage biotechnology company, disclosed that all nine resolutions put to shareholders at its Annual General Meeting held on 12 November 2026 were carried by the requisite majorities.

Key Points

All nine resolutions were carried at the AGM held on 12 November 2026 at 4:00pm AEDT in Melbourne, Australia.
The 10% placement facility (Resolution 3) was approved with 99.73% of poll votes cast in favour.
The re-election of Mr Chris Ntoumenopoulos as a director (Resolution 2) was carried with 99.34% of poll votes in favour.
Options were approved for issue to Mr Jason Carroll (two resolutions), Mr Herwig Janssen, Mr Chris Ntoumenopoulos, Mr Gage Jull, and Dr Daniel Tillett.
The non-binding resolution to adopt the remuneration report (Resolution 1) was carried with 99.76% of poll votes in favour.

AGM Voting Results by Poll

All resolutions were decided by poll. The non-binding remuneration report resolution received 99.76% of poll votes in favour, with 0.24% against. The re-election of Mr Chris Ntoumenopoulos as a director received 99.34% of poll votes in favour and 0.66% against. The approval of the 10% placement facility received 99.73% of poll votes in favour and 0.27% against. The results were disclosed by Entropy Neurodynamics in accordance with Listing Rule 3.13.2 and section 251AA(2) of the Corporations Act 2001.

Options Approved for Directors and Officers

Shareholders approved the issue of options to multiple individuals at the meeting. Resolutions 4 and 6, both relating to the approval of options for Mr Jason Carroll, were each carried with 96.74% of poll votes in favour and 3.26% against. Resolution 5, covering options for Mr Herwig Janssen, was carried with 98.34% in favour. Resolution 7, for Mr Chris Ntoumenopoulos, and Resolution 9, for Dr Daniel Tillett, were each carried with 93.35% in favour. Resolution 8, covering options for Mr Gage Jull, was carried with 96.74% in favour.

Company Background and Filing Authority

Entropy Neurodynamics is a clinical-stage biotechnology company focused on developing proprietary formulations for the administration of psilocin in combination with psychotherapy. The company's lead program, TRP-8803, is a proprietary formulation of IV-infused psilocin. The company disclosed that the AGM filing was authorised by the Board of Entropy Neurodynamics Limited. Proxy vote details and poll results for each resolution were included in the attached document filed with the company update, as required under the Corporations Act 2001.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.